Related Experiment Video
Updated: Feb 24, 2026
Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
Published on: March 29, 2024
Flavonolignans inhibit the arachidonic acid pathway in blood platelets
Michal Bijak1, Joanna Saluk-Bijak2
1Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236, Lodz, Poland. michal.bijak@biol.uni.lodz.pl.
Background:
Arachidonic acid metabolism by cyclooxygenase (COX) is a major pathway for blood platelets' activation, which is associated with pro-thrombotic platelet activity and the production of pro-inflammatory mediators. Inhibition of COX activity is one of the major means of anti-platelet pharmacotherapy preventing arterial thrombosis and reducing the incidence of cardiovascular events. Recent studies have presented that a silymarin (standardized extract of Milk thistle (Silybum marianum)) can inhibit the COX pathway. Accordingly, the aim of our study was to determine the effects of three major flavonolignans (silybin, silychristin and silydianin) on COX pathway activity in blood platelets.
Methods:
We determined the effect of flavonolignans on arachidonic acid induced blood platelet aggregation, COX pathway metabolites formation, as well as COX activity in platelets. Additionally, we analysed the potential mechanism of this interaction using the bioinformatic ligand docking method.
Results:
We observed that tested compounds decrease the platelet aggregation level, both thromboxane A2 and malondialdehyde formation, as well as inhibit the COX activity. The strongest effect was observed for silychristin and silybin. In our in silico study we showed that silychristin and silybin have conformations which interact with the active COX site as competitive inhibitors, blocking the possibility of substrate binding.
Conclusions:
The results obtained from this study clearly present the potential of flavonolignans as novel antiplatelet and anti-inflammatory agents.
Insights
Milk thistle flavonolignans, silybin and silychristin, inhibit cyclooxygenase (COX) activity, reducing platelet aggregation and inflammation. These compounds show potential as novel antiplatelet and anti-inflammatory agents.
Area of Science:
- Biochemistry
- Pharmacology
- Natural Products
Background:
- Cyclooxygenase (COX) pathway in arachidonic acid metabolism is crucial for platelet activation, pro-thrombotic activity, and inflammatory mediator production.
- COX inhibition is a key strategy in anti-platelet pharmacotherapy for preventing arterial thrombosis and cardiovascular events.
- Silymarin, a milk thistle extract, has demonstrated potential in inhibiting the COX pathway.
Purpose of the Study:
- To investigate the effects of three major milk thistle flavonolignans—silybin, silychristin, and silydianin—on cyclooxygenase (COX) pathway activity in blood platelets.
- To evaluate their potential as antiplatelet and anti-inflammatory agents.
Main Methods:
- Assessed the impact of flavonolignans on arachidonic acid-induced platelet aggregation.
- Measured COX pathway metabolite formation and COX enzyme activity in platelets.
- Utilized bioinformatic ligand docking to analyze the interaction mechanism.
Main Results:
- Flavonolignans significantly reduced platelet aggregation, thromboxane A2 and malondialdehyde formation, and inhibited COX activity.
- Silychristin and silybin exhibited the strongest inhibitory effects.
- In silico analysis revealed that silychristin and silybin act as competitive inhibitors by binding to the active COX site.
Conclusions:
- Flavonolignans from milk thistle demonstrate significant antiplatelet and anti-inflammatory properties.
- Silybin and silychristin show particular promise as novel therapeutic agents targeting the COX pathway.
- These findings support the development of flavonolignans for cardiovascular and inflammatory conditions.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...